tailieunhanh - THE CURRENT STATE OF THERAPY FOR AGE-RELATED MACULAR DEGENERATION

Over the past decade, treatment of neovascular age-related macular degeneration has evolved from overall retinal ablation to more targeted and retinal-sparing therapy, beginning with the advent of photodynamic therapy and continuing with the development of inhibitors to vascular endothelial growth factor (VEGF). This article summarizes the key clinical trials with photodynamic and anti- VEGF therapies to provide insight into and a framework around which we can choose the optimal treatments (including dosing) for our patients | Proceedings THE CURRENT STATE OF THERAPY FOR AGE-RELATED MACULAR DEGENERATION Jennifer I. Lim MD ABSTRACT Over the past decade treatment of neovascular age-related macular degeneration has evolved from overall retinal ablation to more targeted and retinal-sparing therapy beginning with the advent of photodynamic therapy and continuing with the development of inhibitors to vascular endothelial growth factor VEGF . This article summarizes the key clinical trials with photodynamic and anti-VEGF therapies to provide insight into and a framework around which we can choose the optimal treatments including dosing for our patients. Our patients now have more choices than ever with a greater chance of not only avoiding vision loss but also perhaps regaining some visual function in a proportion of patients. Ongoing and future studies should help us to answer the questions of optimal dosing and which patient characteristics may predict better outcomes. Adv Stud Ophthalmol. 200 4 5 121-126 Based on a presentation by Dr Lim at a symposium held in conjunction with the Association for Research in Vision and Ophthalmology Annual Meeting in Fort Lauderdale Florida on May 5 2007. Director of Retina Services Department of Ophthalmology and Visual Science University of Illinois Eye and Ear Infirmary Chicago Illinois. Address correspondence to Jennifer I. Lim MD Director of Retina Services Department of Ophthalmology and Visual Science University of Illinois Eye and Ear Infirmary 1855 W. Taylor Street Suite 250 Mail Code 648 Chicago IL 60612. E-mail jennylim@. It has been an interesting and important journey over the ast decade to our current state of treating neovascular age-related macular degeneration AMD . We have evolved from overall ablation of the retina to more targeted and retinal-. par ng therapy. This change began with the advent of photodynamic therapy and continued with the development of inhibitors to vascular endothelial growth factor VEGF with which we can now .

crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.